The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a strategic move to bolster its presence in emerging markets, Ocugen has announced the signing of a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license its OCU400 gene therapy in the MENA region. Under the agreement, Ocugen is eligible to receive sales-related milestone payments totaling up to $255 million. The deal also stipulates that the company will receive royalties equaling 22% of net sales for the therapy, which targets Retinitis Pigmentosa, across the Middle East and North Africa.
This expansion comes as biotechnology firms increasingly compete for regional distribution rights, mirroring moves by peers like Roche's Spark Therapeutics in the ocular gene therapy space. Per market data, the global gene therapy sector is expanding at a compound annual growth rate exceeding 18%, making regional licensing deals a vital source of non-dilutive capital for mid-cap biotech firms aiming to fund advanced clinical trials.
Regarding market performance, OCGN shares stood at $1.47 (at close July 10, 2026), as investors weigh the company's ability to convert framework agreements into realized cash flow. With no immediate sector-specific catalysts in the upcoming economic calendar, market attention will remain fixed on ongoing clinical trial results for OCU400 as the primary driver for the stock's valuation in the medium term.